![](\"https:\/\/mms.businesswire.com\/media\/20260610755620\/en\/2064134\/5\/logo_2023.jpg\"){kind=logo}
<\/a><\/a>\nAll of the resolutions proposed at the Annual General Meeting were duly passed by the shareholders on a poll. The results of the poll, incorporating the proxy votes lodged in advance of the meeting, are set out below.<\/p>
BOSTON--(BUSINESS WIRE)--The Annual General Meeting of PureTech Health plc (LSE: PRTC) (\u201cPureTech\u201d or the \u201cCompany\u201d) was held at 11 a.m. EDT\/4 p.m. BST on Wednesday, June 10, 2026.<\/p> \nAll of the resolutions proposed at the Annual General Meeting were duly passed by the shareholders on a poll. The results of the poll, incorporating the proxy votes lodged in advance of the meeting, are set out below.<\/p><\/a><\/a>
\nResolutions<\/b><\/p><\/td> | \nFor<\/b><\/p><\/td> | \n%<\/b><\/p><\/td> | \nAgainst<\/b><\/p><\/td> | \n%<\/b><\/p><\/td> | \nWithheld<\/b><\/p><\/td> | \nTotal votes cast<\/b><\/p><\/td><\/tr>\n \n001. To approve the Company\u2019s Annual Report and Accounts for year ended 31 December 2025<\/p><\/td> \n148,986,114<\/p><\/td> \n99.97<\/p><\/td> \n46,392<\/p><\/td> \n0.03<\/p><\/td> \n10,803<\/p><\/td> \n149,032,506<\/p><\/td><\/tr>\n \n002. To approve the Directors\u2019 Remuneration Report<\/p><\/td> \n142,375,459<\/p><\/td> \n95.84<\/p><\/td> \n6,172,764<\/p><\/td> \n4.16<\/p><\/td> \n495,086<\/p><\/td> \n148,548,223<\/p><\/td><\/tr>\n \n003. To re-elect Ms. Sharon Barber-Lui as a Director<\/p><\/td> \n143,421,622<\/p><\/td> \n96.23<\/p><\/td> \n5,617,352<\/p><\/td> \n3.77<\/p><\/td> \n4,335<\/p><\/td> \n149,038,974<\/p><\/td><\/tr>\n \n004. To re-elect Dr. Michele Holcomb as a Director<\/p><\/td> \n148,415,257<\/p><\/td> \n99.58<\/p><\/td> \n622,164<\/p><\/td> \n0.42<\/p><\/td> \n5,888<\/p><\/td> \n149,037,421<\/p><\/td><\/tr>\n \n005. To re-elect Dr. John LaMattina as a Director<\/p><\/td> \n139,575,205<\/p><\/td> \n93.65<\/p><\/td> \n9,462,210<\/p><\/td> \n6.35<\/p><\/td> \n5,894<\/p><\/td> \n149,037,415<\/p><\/td><\/tr>\n \n006. To re-elect Dr. Robert Langer as a Director<\/p><\/td> \n142,363,975<\/p><\/td> \n95.76<\/p><\/td> \n6,298,309<\/p><\/td> \n4.24<\/p><\/td> \n381,025<\/p><\/td> \n148,662,284<\/p><\/td><\/tr>\n \n007. To elect Mr. Robert Lyne as a Director<\/p><\/td> \n148,496,575<\/p><\/td> \n99.64<\/p><\/td> \n539,340<\/p><\/td> \n0.36<\/p><\/td> \n7,394<\/p><\/td> \n149,035,915<\/p><\/td><\/tr>\n \n008. To re-elect Ms. Kiran Mazumdar-Shaw as a Director<\/p><\/td> \n122,266,593<\/p><\/td> \n82.04<\/p><\/td> \n26,769,322<\/p><\/td> \n17.96<\/p><\/td> \n7,394<\/p><\/td> \n149,035,915<\/p><\/td><\/tr>\n \n009. To reappoint PricewaterhouseCoopers LLP as Auditors of the Company<\/p><\/td> \n148,776,133<\/p><\/td> \n99.83<\/p><\/td> \n257,001<\/p><\/td> \n0.17<\/p><\/td> \n10,175<\/p><\/td> \n149,033,134<\/p><\/td><\/tr>\n \n010. To authorize the Audit Committee to determine the Auditors' remuneration<\/p><\/td> \n148,750,724<\/p><\/td> \n99.81<\/p><\/td> \n286,702<\/p><\/td> \n0.19<\/p><\/td> \n5,883<\/p><\/td> \n149,037,426<\/p><\/td><\/tr>\n \n011. To authorize the allotment of shares<\/p><\/td> \n147,843,913<\/p><\/td> \n99.61<\/p><\/td> \n578,544<\/p><\/td> \n0.39<\/p><\/td> \n620,852<\/p><\/td> \n148,422,457<\/p><\/td><\/tr>\n \n012. To disapply pre-emption rights<\/p><\/td> \n147,589,781<\/p><\/td> \n99.39<\/p><\/td> \n905,323<\/p><\/td> \n0.61<\/p><\/td> \n548,205<\/p><\/td> \n148,495,104<\/p><\/td><\/tr>\n \n013. To further disapply pre-emption rights for acquisitions and specified capital investments.<\/p><\/td> \n146,398,006<\/p><\/td> \n98.59<\/p><\/td> \n2,096,790<\/p><\/td> \n1.41<\/p><\/td> \n548,513<\/p><\/td> \n148,494,796<\/p><\/td><\/tr>\n \n014. To authorize market purchase of own shares<\/p><\/td> \n148,852,410<\/p><\/td> \n99.90<\/p><\/td> \n155,201<\/p><\/td> \n0.10<\/p><\/td> \n35,698<\/p><\/td> \n149,007,611<\/p><\/td><\/tr>\n \n015. To authorize general meetings to be called on not less than 14 clear days\u2019 notice<\/p><\/td> \n148,679,278<\/p><\/td> \n99.76<\/p><\/td> \n360,501<\/p><\/td> \n0.24<\/p><\/td> \n3,530<\/p><\/td> \n149,039,779<\/p><\/td><\/tr>\n<\/table> \nNotes:<\/p> \nAbout PureTech Health<\/b><\/p> \nPureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval. By identifying, shaping, and de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders.<\/p> |